What is CAP?
Founded in 1993, the Corporate AACE Partnership (CAP) is a forum whose purpose is to develop an open dialogue between industry and AACE in the furtherance of patient care. The mission of the CAP is to facilitate the improvement of endocrine patient care by working with industry in areas of mutual interest.
Abbott Diabetes Care
Amarin Pharma Inc.
Boehringer Ingelheim Pharmaceuticals, Inc.
Health Monitor Network
Intarcia Therapeutics, Inc.
Lilly USA, LLC
Merck-Pfizer Diabetes Collaboration
Takeda Pharmaceuticals U.S.A, Inc.
To learn more about the CAP or to request more details about joining the CAP, e-mail [email protected].